恒瑞医药(01276)：注射用SHR-A2009获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, a novel antibody-drug conjugate targeting HER3 [1] Company Summary - SHR-A2009 is designed to specifically bind to HER3 on the surface of tumor cells, leading to internalization and subsequent release of cytotoxic agents within lysosomes to kill cancer cells [1] - This drug is notable as there are currently no similar drugs approved for market globally [1]